Article

Photocoagulator gets FDA marketing OK

Santa Clara, CA—Lumenis Ltd. has received FDA clearance to market its Novus 3000, a 532 nm diode-pumped solid-state (DPSS) photocoagulator.

Santa Clara, CA-Lumenis Ltd. has received FDA clearance to market its Novus 3000, a 532 nm diode-pumped solid-state (DPSS) photocoagulator.

The new product is an improved version of its Novus 2000, which has about 1,500 units installed worldwide. The device offers up to 3 watts of power through semiconductor-based technology, and has a color touch-screen interface and liquid crystal display remote control for instant adjustments to treatment parameters. Novus 3000 features built-in storage for a laser indirect ophthalmoscope, remote control, foot switch, and other accessories.

Multiple memory locations allow ophthalmologists to save and recall preferences, and two dedicated illumination sources expand treatment options. Two delivery devices can be attached at once for switching during procedures.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.